Otonomy Provides Update on OTIVIDEX® Program
July 06, 2020 16:02 ET
|
Otonomy, Inc.
SAN DIEGO, July 06, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an...
Otonomy Provides Update on Clinical Trials and Development Programs
June 15, 2020 16:05 ET
|
Otonomy, Inc.
Results from Phase 3 trial of OTIVIDEX® in Ménière’s disease expected in first quarter of 2021Results from Phase 1/2 trial of OTO-313 in tinnitus expected in July 2020Results from Phase 1/2 trial of...
Otonomy to Present at Raymond James 2020 Human Health Innovation Conference
June 11, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020
June 10, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Host Pipeline Program Update Conference Call and Webcast
June 08, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program
May 12, 2020 08:00 ET
|
Otonomy, Inc.
SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 07, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported...
Otonomy Provides Business Update Related to COVID-19 Pandemic
April 09, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a...
Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
February 27, 2020 16:15 ET
|
Otonomy, Inc.
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseCurrent capital funds operations into 2021 Conference call and webcast today at 4:30...
Otonomy to Present at Two Upcoming Investor Conferences
February 24, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...